Fondita European Small Cap

Europe's smaller companies that have already succeeded in their internationalisation efforts

Our funds
The fund

Fondita European Small Cap is an equity fund that invests in a limited number of small and medium-sized European quality companies with a market capitalisation of up to EUR 4 billion. The fund has a concentrated portfolio and invests in companies, whose long-term growth is mainly driven by structural factors and societal changes.

Small caps

The fund invests in small caps that have already succeeded and can showcase a business model that works internationally. The small cap segment holds many family-owned companies that have gone from being local champions to bringing their know-how to the world.

Such companies focus on demographic changes in terms of both individual health and well-being, as well as changing consumer behaviours, the widespread digitisation of society, an increased focus on the environment and climate, and the manufacturing industry’s progress towards increasingly automated processes.

These are smaller listed companies that have shown stronger growth and greater potential. They often have both their own niche and a solid market position resulting in strong profitability.

Sustainability
Read more about the fund’s sustainability principles:
Fund facts

30.11.2023

Fund size (M€)
48,0
ISIN (A)
FI0008814686
ISIN (B)
FI0008814694
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
5/7
SFDR Classification
Article 8
Top holdings
Bufab (SE)
4,3 %
Kontron (AT)
4,1 %
Dermapharm Holding (DE)
4,1 %
Borregaard (NO)
3,9 %
Siegfried Holding (DE)
3,9 %
Germany
22 %
Sweden
19 %
Switzerland
13 %
Finland
6 %
Italy
7 %
Return
1 month
14,1 %
3 months
-3,9 %
6 months
-8,8 %
YTD
-6,1 %
1 year
-10,2 %
3 years
-9,3 %
5 years
7,1 %
10 years
42,1 %
since launch (19.5.2009)
229,0 %
since launch p.a.
8,5 %
Sector division
Information Technology
29 %
Industrials
30 %
Health Care
19 %
Consumer Discretionary
8 %
Materials
6 %
Other
6 %
Financials
3 %
Top 10 holdings
Bufab (SE)
4,3 %
Kontron (AT)
4,1 %
Dermapharm Holding (DE)
4,1 %
Borregaard (NO)
3,9 %
Siegfried Holding (DE)
3,9 %
Laboratorios Frama Rovi (ES)
3,5 %
Jenoptik (DE)
3,4 %
Kardex Group (CH)
3,2 %
NCAB Group (SE)
3,2 %
Inficon Holding (CH)
3,2 %
Country division
Germany
22 %
Sweden
19 %
Switzerland
13 %
Finland
6 %
Italy
7 %
Norway
7 %
Other
26 %
Currency exposure
EUR
53 %
SEK
19 %
CHF
13 %
GBP
5 %
NOK
7 %
DKK
3 %
Fees
TER
2,00 %
Subscription fee
0,00 %
Redemption fee
1,00 %

Total client relationship allow for changes in tariff rate.

Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
KID NO
Prospectus
REPORTS
Monthly report
Annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Responsible Investment Policy

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
Strong results from Fondita’s engagements as lead signatory in the CDP 2023 Non-Disclosure Campaign

Fondita acted as the lead signatory in CDP’s (former Carbon Disclosure Project) 2023 Non-Disclosure Campaign. The NDC runs alongside the main CDP ... Read more

Fondita Healthcare – first healthcare fund in Finland with the highest SFDR sustainability classification, Article 9

Fondita’s global actively managed healthcare fund, Fondita Healthcare, is classified as an Article 9 fund (previously Article 8) as of 1.11.2023. According ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online